Category: Uncategorized
As part of its Inventive Step series, MedNous published an article by HaemaLogiX co-founder Rosanne Dunn in its March issue.
The article detailed how, for decades, a therapy for multiple myeloma that selects for the malignant cell and spares its benign counterpart has only been a theoretical idea. However, research from Dunn and her team at HaemaLogix has finally made this approach a reality.
Reach more about the approach here.
CuraCell TX AB announced that the first patient has been successfully included into its ongoing Phase I/IIa clinical trial evaluating the company’s novel autologous Tumor-Infiltrating Lymphocyte (TIL) therapy, CC-38, for patients with metastatic colorectal and metastatic prostate cancer.
Read the full announcement here.
HaemaLogiX is highlighted in Drug Target Review for work identifying KMA and LMA antigens as promising therapeutic targets in plasma cell dyscrasias, a group of disorders that includes multiple myeloma. The piece outlines why these antigens are considered high‑value: they show selective expression on malignant plasma cells and present opportunities for targeted modalities such as antibody–drug conjugates and engineered cell therapies.
Targeting KMA and LMA could improve tumour specificity and reduce off‑target toxicity compared with broader approaches, potentially enabling deeper remissions for patients with relapsed or refractory disease. The article highlights our client’s role in advancing antigen validation and preclinical development, including biomarker characterisation and early translational studies that support clinical candidate selection.
Read the full story here.
Cereno Scientific has announced a regulatory milestone that materially shortens the development path for CS014, with Swedish authorities approving a focused FDA‑aligned PK study that replaces the need for further safety work and a Phase IIa trial.
Rather than signalling “another Phase I” this streamlined design is intended to accelerate CS014 directly toward Phase IIbin PH‑ILD by generating the comparative bioavailability data the FDA has already indicated will be sufficient for progression.
The study’s crossover PK approach in healthy volunteers is therefore a strategic shortcut, not a reset, enabling Cereno to leverage existing VPA data, strengthen the safety package efficiently, and keep the programme on track for Phase II initiation in early 2027.
More details on the news can be found on the Cereno Scientific website here.
HaemaLogiX has been in the spotlight as it advances a differentiated approach to multiple myeloma, the world’s second‑largest blood cancer. In a recent episode of BioBiz Buzz, CEO Dr Chris Baldwin outlined how the company is developing highly specific therapies targeting two novel antigens, KMA and LMA, found only on malignant plasma cells.
Its lead antibody, KappaMab, has already shown an 83% response rate in Phase IIb trials, while its partnered KMA.CAR‑T programme is progressing through early clinical development at the Peter MacCallum Cancer Centre.
With plans for an ASX IPO in 2026, HaemaLogiX is expanding its pipeline, scaling CAR‑T manufacturing, and positioning itself to address a major unmet need in a market exceeding $23 billion annually.
Listen to the full episode here: www.buzzsprout.com/2467194/episodes/18829609
etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one of its key collaborators, Almirall, a leading medical dermatology company, nominated LAD116 as a novel therapy targeting non-melanoma skin cancer for further development in IND enabling studies. LAD116 is based on etherna’s intratumoral mRNA/LNP platform for therapies intended to generate a potent immune response directly within the tumor microenvironment. The collaboration with Almirall on this potential new therapy will now focus on manufacturing and producing GMP-grade material for IND enabling studies and intended Phase I clinical trials.
Bernard Sagaert, CEO, etherna, added:
"This collaboration is a perfect example of what can be achieved when teams are fully aligned and driven to succeed. The combined efforts of both companies to discover and advance an mRNA-LNP based therapy to preclinical candidate nomination, on time and on budget, has been outstanding. We are extremely happy to continue to support Almirall as they advance this promising approach for non-melanoma skin cancer patients."
Karl Ziegelbauer, Chief Scientific Officer, Almirall, commented:
“Almirall is committed to advancing innovation in medical dermatology to address significant unmet medical needs. We are very excited to advance this innovative intratumoral approach to potentially treat patients with non-melanoma skin cancer and we are delighted to see rapid progress of our collaboration with etherna based on their mRNA and LNP capabilities."
About etherna
etherna is a leading technology platform company pioneering the development of mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP. With over a decade of expertise, the company provides pharma and biotech partners with an integrated suite of proprietary platforms, including customizable lipid nanoparticles (cLNPs) and advanced mRNA chemistry to enable the delivery of differentiated and efficacious RNA therapeutics. Founded in 2013 as a spin-off from the Vrije Universiteit Brussel (VUB), etherna has evolved from a developer of immunotherapies into a key strategic partner for the global life sciences industry, supporting projects from early research over development to GMP manufacturing. The company is headquartered in Niel, Belgium, with R&D facilities in Ghent and commercial operations in the U.S. and Asia.
Media Contact: Richard.Hayhurst@59north.bio
Jonas Båtelson of CuraCell has been featured in Citeline’s In Vivo, offering a sharp analysis of why platform‑driven models are becoming essential to the future of cell therapy. In his commentary, Båtelson argues that the sector’s next wave of winners will be those able to industrialise innovation by building scalable, modular platforms that reduce cost, accelerate development, and enable a broader pipeline of therapies.
His perspective positions CuraCell at the forefront of the industry conversation, highlighting the company’s strategic focus on technologies that can unlock true commercial viability for advanced cell‑based treatments.
Read the full article here.
Albus Health featured in The Pharma Navigator’s latest coverage on the future of clinical trial measurement. In the piece, CEO Mikesh Udani highlights how Albus Health’s passive, non‑contact respiratory monitoring technology is helping the industry move beyond burdensome, manual data collection toward richer, more continuous, patient‑centric insights.
His perspective underscores a growing shift across life sciences: measuring what truly matters to patients while reducing friction in trial participation. You can listen to, and read the article here.
What to expect from 2026? We asked some of our journalist friends working in life sciences and healthtech. Here are answers from BioCentury, Clarivate, In Vivo, Scrip, Nature Biotech, Labiotech, Medtech Insight GlobalData, BioPharm International and Advancing RNA. We’ve included links to their relevant articles.
Please click here to read more...